Skip to main content
S 79 118th Congress Senate Commerce Administrative remedies Department of Commerce Drug safety, medical device, and laboratory regulation Food and Drug Administration (FDA) Intellectual property Intergovernmental relations

Interagency Patent Coordination and Improvement Act of 2023

Introduced: January 25, 2023 Introduced by: Durbin, Richard J. Democratic · Illinois See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Jan 25, 2023
Read twice and referred to the Committee on the Judiciary.
Jan 25, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Interagency Patent Coordination and Improvement Act of 2023

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

What's happening now March 1, 2023

Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.

 Related & companion bills 1
  • HR 1717 Identical bill Interagency Patent Coordination and Improvement Act of 2023
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 4
All 4 Democratic 2 Republican 2
D
Welch, Peter
Vermont · Feb 7, 2023
 D
Coons, Christopher A.
Delaware · Jan 25, 2023
 R
Grassley, Chuck
Iowa · Jan 25, 2023
 R
Tillis, Thomas
North Carolina · Jan 25, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 79: Interagency Patent Coordination and Improvement Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-79/
MLA
"S. 79: Interagency Patent Coordination and Improvement Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-79/.
Bluebook (legal)
S. 79, 118th Cong. (2026), https://openamerica.io/bill/118-S-79/.
Markdown link
[S. 79: Interagency Patent Coordination and Improvement Act of 2023](https://openamerica.io/bill/118-S-79/)
Report a problem